{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:31:12Z","timestamp":1792463472985,"version":"4.5.0"},"reference-count":59,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>To explore long-term changes in intra and inter-class choices between generic compounds, this paper investigates the market trends of two antihypertensive drug classes that have closely related pharmacological mechanisms\u2014angiotensin convertase enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). We analysed the development of ACEI and ARB markets between 2001 and 2016 in nine European countries, covering the genericization transition periods of both therapeutic groups. The analysis was undertaken on the level of the active pharmaceutical ingredients (API) and focused on international and country-specific diffusion patterns. Comparison of ARB and ACEI therapies shows that although ARBs became off-patent during the observed period, and have a clinical advantage in terms of the adverse event profile over ACEIs, the increasing dominance of ARBs cannot be identified. One explanation is that ACEI therapies became generics earlier, relocating competition to the level of brands, while competition among ARBs remained at the level of the APIs. As for intra-class drug preferences, it was observed that the long-term trends show that ramipril outperformed its ACEI competitors, even though the kinetics and the rank order of preferred active compounds were inconsistent among markets. The diffusion of clinically preferable therapies seems to be ultimately supported by generic entries. In Eastern European countries, the emergence of generic markets has not only improved access to ACE inhibitors and ARBs, but has been a prerequisite for changing preferences. In contrast, genericization resulted in the relative anchoring of prior, branded era-based preferences in some Western European countries, which may be attributed to the role of the cessation of promotion and the fixity of prescription behaviour.<\/jats:p>","DOI":"10.3390\/ijerph18189429","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T10:24:25Z","timestamp":1631010265000},"page":"9429","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Drugs Becoming Generics\u2014The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients"],"prefix":"10.3390","volume":"18","author":[{"given":"Bence","family":"Kov\u00e1cs","sequence":"first","affiliation":[{"name":"Institute of Marketing, Corvinus University of Budapest, 1093 Budapest, Hungary"},{"name":"Global Pipeline and Portfolio Project Management Department, Gedeon Richter Plc., 1103 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4664-5405","authenticated-orcid":false,"given":"Mikl\u00f3s","family":"Darida","sequence":"additional","affiliation":[{"name":"Medical Division, Gedeon Richter Plc.,1103 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0409-7471","authenticated-orcid":false,"given":"Judit","family":"Simon","sequence":"additional","affiliation":[{"name":"Institute of Marketing, Corvinus University of Budapest, 1093 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"ref_1","unstructured":"Decsi, T. (2011). Evidence-Based Medicine. [A Bizony\u00edt\u00e9kokon Alapul\u00f3 Orvosl\u00e1s], Medicina Kiad\u00f3."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence based medicine: What it is and what it isn\u2019t","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1345\/aph.1K283","article-title":"Challenges to evidence-based prescribing in clinical practice","volume":"42","author":"Mamdani","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3399\/bjgp12X652382","article-title":"Barriers to GPs\u2019 use of evidence-based medicine: A systematic review","volume":"62","author":"Zwolsman","year":"2012","journal-title":"Br. J. Gen. Pract."},{"key":"ref_5","first-page":"49","article-title":"The impact of scientific evidence and price level of hypertension drug therapies on their market performance\u2014A Europe based analysis","volume":"48","author":"Simon","year":"2017","journal-title":"Vez. Bp. Manag. Rev."},{"key":"ref_6","unstructured":"Sara, B., Jonathan, D.Q., and Germ\u00e1n, V. (1997). Public-Private Roles in the Pharmaceutical Sector. Implications for Equitable Access and Rational Drug Use, WHO."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ding, M., Eliashberg, J., and Stremersch, S. (2014). The pharmaceutical industry: Specificity, challenges, and what you can learn from this book. Innovation and Marketing in the Pharmaceutical Industry, Springer.","DOI":"10.1007\/978-1-4614-7801-0_1"},{"key":"ref_8","first-page":"1","article-title":"Pharmaceutical regulation in 15 European countries","volume":"18","author":"Panteli","year":"2016","journal-title":"Health Syst. Transit"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ding, M., Eliashberg, J., and Stremersch, S. (2014). Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development. Innovation and Marketing in the Pharmaceutical Industry, Springer.","DOI":"10.1007\/978-1-4614-7801-0"},{"key":"ref_10","first-page":"538","article-title":"Pharmaceutical followers","volume":"31","author":"Arcidiacono","year":"2013","journal-title":"Pharm. Follow."},{"key":"ref_11","first-page":"1","article-title":"How to explain price gaps between me-too Drugs","volume":"168","author":"Bergua","year":"2012","journal-title":"Quest. \u00c9conomie St."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/bmj.38582.703866.AE","article-title":"\u201cBreakthrough\u201d drugs and growth in expenditure on prescription drugs in Canada","volume":"331","author":"Morgan","year":"2005","journal-title":"BMJ"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00019053-200220003-00002","article-title":"Returns on research and development for 1990s new drug introductions","volume":"20","author":"Grabowski","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Van der Gronde, T., Groot, C.A.U.-D., and Pieters, T. (2017). Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS ONE.","DOI":"10.1371\/journal.pone.0182613"},{"key":"ref_15","unstructured":"European Commission (2009). Pharmaceutical Sector Inquiry Final Report, European Commission."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Conti, R., and Berndt, E. (2014). Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001\u20132007, NBER.","DOI":"10.3386\/w20016"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1468-0327.2008.00207.x","article-title":"Competition in off-patent drug markets: Issues, regulation and evidence","volume":"23","author":"Kanavos","year":"2008","journal-title":"Econ. Policy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0144-8188(00)00030-2","article-title":"Generic take-up in the pharmaceutical market following patent expiry","volume":"20","author":"Hudson","year":"2000","journal-title":"Int. Rev. Law Econ."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/mde.1356","article-title":"Generic competition and market exclusivity periods in pharmaceuticals","volume":"28","author":"Grabowski","year":"2007","journal-title":"Manag. Decis. Econ."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.healthpol.2014.08.005","article-title":"Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States","volume":"118","author":"Kanavos","year":"2004","journal-title":"Health Policy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMp1408376","article-title":"High-cost generic drugs\u2014Implications for patients and policymakers","volume":"371","author":"Alpern","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1182\/blood-2015-11-680058","article-title":"Strategies that delay or prevent the timely availability of affordable generic drugs in the United States","volume":"127","author":"Jones","year":"2016","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1057\/palgrave.jgm.4940095","article-title":"Battle for the market: Branded drug companies\u2019 secret weapons generic drug makers must know","volume":"3","author":"Hess","year":"2005","journal-title":"J. Generic Med."},{"key":"ref_24","unstructured":"(2016). Summary of Commission Decision of 9 July 2014 relating to a proceeding under Articles 101 and 102 of the Treaty on the Functioning of the European Union (Case AT.39612\u2014Perindopril (Servier)) (notified under document C(2014) 4955). Off. J. Eur. Union, 393, 7\u201312. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:52016XC1025(01)&from=EN."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Carone, G., Schwierz, C., and Xavier, A. (2012). Cost-containment policies in public pharmaceutical spending in the EU. Econ. Financ. Aff.","DOI":"10.2139\/ssrn.2161803"},{"key":"ref_26","unstructured":"Belloni, A., Morgan, D., and Paris, V. (2016). Pharmaceutical expenditure and policies. OECD Health Work. Pap."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Danzon, P.M., and Furukawa, M.F. (2011). Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets, National Bureau of Economic Research. No. w17226.","DOI":"10.3386\/w17226"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2471\/BLT.13.129114","article-title":"Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries","volume":"92","author":"Leopold","year":"2014","journal-title":"Bull. World Health Organ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40258-016-0300-z","article-title":"How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries","volume":"15","author":"Vogler","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"key":"ref_30","first-page":"55","article-title":"Managing the diffusion of pharmaceutical innovations: Conclusions from a literature review","volume":"2","year":"2013","journal-title":"Pannon. Manag. Rev."},{"key":"ref_31","first-page":"792","article-title":"Gy\u00f3gyszerek terjed\u00e9s\u00e9nek vizsg\u00e1lata Cox-regresszi\u00f3val","volume":"92","author":"Benedek","year":"2014","journal-title":"Stat. Szle."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lubl\u00f3y, \u00c1. (2014). Factors affecting the uptake of new medicines: A systematic literature review. BMC Health Serv. Res., 14.","DOI":"10.1186\/1472-6963-14-469"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/10810730490271430","article-title":"Forty years of diffusion of innovations: Utility and value in public health","volume":"9","author":"Haider","year":"2004","journal-title":"J. Health Commun."},{"key":"ref_34","unstructured":"Rogers, E.M. (1983). Diffusion of Innovations, Free Press. [3rd ed.]."},{"key":"ref_35","unstructured":"Denig, P. (1994). Drug Choice in Medical Practice: Rationales, Routines and Remedies, University of Groningen."},{"key":"ref_36","first-page":"18","article-title":"ACE-inhibitors\u2014An analysis of marketing strategy","volume":"28","author":"Peny","year":"1994","journal-title":"Scrip. Mag."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1161\/01.CIR.0000090572.51900.92","article-title":"Should evidence-based proof of drug efficacy be extrapolated to a \u201cClass of Agents\u201d?","volume":"108","author":"Furberg","year":"2003","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0735-1097(01)01161-5","article-title":"Are all angiotensin-converting enzyme inhibitors interchangeable?","volume":"37","author":"Furberg","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3810\/pgm.2013.07.2687","article-title":"Not all angiotensin-converting enzyme inhibitors are equal: Focus on ramipril and perindopril","volume":"125","author":"Dinicolantonio","year":"2013","journal-title":"Postgrad. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jval.2015.08.005","article-title":"Appropriateness of prescriptions of recommended treatments in organisation for economic co-operation and development health systems: Findings based on the long-term registry of the European society of cardiology on heart failure","volume":"18","author":"Maggioni","year":"2015","journal-title":"Value Health"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Othman, N., Vitry, A., and Roughead, E.E. (2009). Quality of pharmaceutical advertisements in medical journals: A systematic review. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006350"},{"key":"ref_42","first-page":"46","article-title":"Are claims of advertisements in medical journals supported by RCts?","volume":"68","author":"Heimans","year":"2010","journal-title":"Neth. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(03)12118-6","article-title":"Accuracy of pharmaceutical advertisements in medical journals","volume":"361","author":"Villanueva","year":"2003","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMsa1202397","article-title":"A Randomized Study of How Physicians Interpret Research Funding Disclosures","volume":"367","author":"Kesselheim","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Fickweiler, F., Fickweiler, W., and Urbach, E. (2017). Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians\u2019 attitudes and prescribing habits: A systematic review. BMJ Open.","DOI":"10.1136\/bmjopen-2017-016408"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Spurling, G.K., Mansfield, P.R., Montgomery, B.D., Lexchin, J., Doust, J., Othman, N., and Vitry, A.I. (2010). Information from pharmaceutical companies and the quality, quantity, and cost of physicians\u2019 prescribing: A systematic review. PLoS Med., 7.","DOI":"10.1371\/journal.pmed.1000352"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1016\/j.socscimed.2006.07.019","article-title":"Determinants for the adoption of angiotensin II receptor blockers by general practitioners","volume":"63","author":"Greving","year":"2006","journal-title":"Soc. Sci. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1287\/mnsc.1070.0718","article-title":"The debate on influencing doctors\u2019 decisions: Are drug characteristics the missing link?","volume":"53","author":"Venkataraman","year":"2007","journal-title":"Manag. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1287\/mksc.2015.0971","article-title":"Drug Detailing and Doctors\u2019 Prescription Decisions: The Role of Information Content in the Face of Competitive Entry","volume":"35","author":"Kappe","year":"2016","journal-title":"Mark. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1468-0262.2005.00612.x","article-title":"Uncertainty and learning in pharmaceutical demand","volume":"73","author":"Crawford","year":"2005","journal-title":"Econometrica"},{"key":"ref_51","unstructured":"WHOCC\u2014ATC\/DDD (2018, March 29). Index. Available online: https:\/\/www.whocc.no\/atc_ddd_index\/?code=C09."},{"key":"ref_52","unstructured":"WHO\u2014DDD (2021, August 03). Definition. Available online: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/about-ddd."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Malhotra, N.K., Jain, A.K., Patil, A., Pinson, C., and Wu, L. (2010). Consumer cognitive Complexity and the Dimensionality of Multidimensional Scaling Configurations, Emerald Group Publishing Limited.","DOI":"10.1108\/S1548-6435(2010)0000007010"},{"key":"ref_54","unstructured":"Tan, P.N., Steinbach, M., and Kumar, V. (2006). Introduction to Data Mining, Pearson Education."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.21037\/jtd.2017.04.59","article-title":"The great challenge of the public health system in Spain","volume":"9","author":"Avanzas","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_56","first-page":"1","article-title":"France: Health system review","volume":"17","author":"Chevreul","year":"2015","journal-title":"Health Syst. Transit."},{"key":"ref_57","unstructured":"NICE (2016). Hypertension in Adults: Diagnosis and Management. Guidance and Guidelines, NICE. Available online: https:\/\/www.nice.org.uk\/guidance\/cg127."},{"key":"ref_58","unstructured":"North of England Hypertension Guideline Development Group (2004). Essential Hypertension: Managing Adult Patients in Primary Care, National Institute for Health and Clinical Excellence."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3399\/bjgp12X630232","article-title":"Management of hypertension in adults in primary care: NICE guideline","volume":"62","author":"McCormack","year":"2021","journal-title":"Br. J. Gen. Pract. J. R. Coll. Gen. Pract."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/18\/9429\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:57:46Z","timestamp":1760165866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/18\/9429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":59,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["ijerph18189429"],"URL":"https:\/\/doi.org\/10.3390\/ijerph18189429","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,7]]}}}